Pharmacokinetic, Safety, Tolerability, Immunogenicity, and Pharmacodynamic Study of SB12 in Healthy Subjects

NCT03722329 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Eculizumab

Sponsor

Samsung Bioepis Co., Ltd.